ClinicalTrials.gg
CompletedNCT03207282TRALUpdated Apr 27, 2025

Treatment Resistant Depression in America Latina

An observational study in Depressive Disorder, Treatment-Resistant, sponsored by Janssen-Cilag, S.A.. Completed at 33 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,539
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · Johnson & Johnson.

Started
2017
with 1 other
Observational
4 of 21
none open now
Registered
13th of 21
by date

Among the 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson, this one is one of 2 that started in 2017, is one of 4 observational ones, and was the 13th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

1 of the 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries: Argentina, Brazil, Colombia and Mexico; and to evaluate all and depression-related healthcare resource utilization in TRD participants.

03

Conditions studied

  • Depressive Disorder, Treatment-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study population consists of participants with Major Depressive Disorder (MDD) being treated in a psychiatry reference site (clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries and will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) among MDD participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1:

  • Major depressive disorder (MDD) diagnosis according to the , 4th edition (DSM-IV), that was confirmed by MINI International Neuropsychiatric Interview, 5.0 version (MINI)
  • Treated or untreated participants with a new or continued episode of depression at the time of the enrolment
  • Participants must be capable of completing the corresponding assessments in the study
  • Participants must be capable of signing the form

Phase 2:

  • Diagnosis of Treatment Resistant Depression (TRD), to be described by the investigator, based on the criteria:

    1. Adequate follow-up and treatment with at least 2 antidepressants
    2. Without complete response to treatment (based on Montgomery-Asberg Depression Rating Scale [MADRS])

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed of psychosis, schizophrenia, bipolar disorder, schizoaffective disorder, or dementia
  • Participants with substance dependence considered serious by the investigator
  • Participant currently participating in another clinical study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,539 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with Diagnosis of Depression

    Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Resistant Depression (TRD)

    Prevalence of TRD will be assessed as percentage of participants with TRD among Major Depressive Disorder (MDD) participants.

    Time frame: Baseline (Day 1)

  2. Healthcare Resource Utilization in TRD Participants

    Healthcare resources utilized in TRD participants will be estimated.

    Time frame: Up to Month 12

Secondary outcomes

  1. Demographic Characteristics of TRD Participants

    Demographic characteristics (such as age and gender) of TRD participants will be assessed at baseline.

    Time frame: Baseline (Day 1)

  2. Number of Participants With Comorbid Conditions

    Comorbid conditions of TRD participants will be assessed at baseline.

    Time frame: Baseline (Day 1)

  3. Treatment Patterns Over Time for TRD Participants

    Treatment patterns of TRD participants will be assessed over time.

    Time frame: Baseline (Day 1) up to Month 12

  4. Treatment Duration for MDD

    Treatment duration is defined as the time interval between baseline and time to next therapy (since the date of the first and second regimen to the start of third regimen).

    Time frame: Baseline (Day 1) up to Month 12

  5. Treatment Pattern for TRD Participants by Line

    Treatment patterns for TRD participants will be determined by distribution of every line of the treatment regimen including pharmaceutical and non-pharmaceutical treatments.

    Time frame: Baseline (Day 1) up to Month 12

  6. Sequence of Drugs

    Sequence of drugs taken by TRD participants will be determined.

    Time frame: Baseline (Day 1) up to Month 12

  7. Severity of Symptoms as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Score

    The MADRS is a 10 item scale for the evaluation of depressive symptoms (Montgomery et al 1979). The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. Each MADRS item is rated on a 0 to 6 scale with a total score ranging from 0 60. Higher MADRS scores indicate higher levels of depressive symptoms (more severe condition) and lower scores indicate a decreased severity of depression.

    Time frame: Baseline (Day 1), Month 3, 6, 9 and 12

  8. Level of Disability as Measured by Sheehan Disability Scale (SDS)

    SDS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. To get a total score add up the 3 individual scores and the total score ranges from "0 = unimpaired" to "30 = highly impaired". Higher scores indicate worsening.

    Time frame: Baseline (Day 1), Month 6, and 12

  9. Suicidality Risk (Ideation and Attempts) as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Suicidal ideation or behavior will be measured using C SSRS score. C-SSRS is a clinician rated assessment of suicidal behavior and/ or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 yes/no items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

    Time frame: Baseline (Day 1), Month 3, 6, 9, and 12

  10. Healthcare Costs in TRD Participants

    Total healthcare costs and healthcare costs related to depression will be determined in TRD participants.

    Time frame: Up to Month 12

  11. Indirect Cost Associated With Work Productivity Loss

    Work productivity loss was measured by Work Productivity and Activity Impairment Questionnaire (WPAI). The WPAI is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on the job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline (Day 1) up to Month 12

  12. Indirect Cost Associated With Daily Functioning Loss

    Indirect cost associated with daily functioning loss will be determined.

    Time frame: Baseline (Day 1) up to Month 12

  13. Indirect Cost Associated With Caregiver Burden

    Indirect cost associated with caregiver burden will be determined.

    Time frame: Baseline (Day 1) and Month 12

  14. Indirect Cost Associated With Quality of Life

    Quality of life will be measured by EuroQol-5 Dimension (EQ-5D). The EQ-5D descriptive system comprises the following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 3 levels of perceived problems (Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." The descriptive system can be represented as a health state. The EQ-VAS self-rating records the respondent's own assessment of his or her overall health status, on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline (Day 1) and Month 12

07

Study locations

33 sites
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
    Ciudad Autonoma de Buenos Aires, C1425AHQ, Argentina
  • CESASIN
    Ciudad de Mendoza, 5500, Argentina
  • Instituto DAMIC
    Cordoba, X5003DCE, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Ávila
    La Plata, B1904ADM, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • Universidade Federal De Minas Gerais - Hospital das Clínicas
    Belo Horizonte, 30130-100, Brazil
  • Instituto De Neurociencias Dr. Quevedo Hospital Sao Sebastiao
    Criciúma, 88801-250, Brazil
  • Trial Tech Tecnologia em Pesquisas com Medicamentos
    Curitiba, 80240-280, Brazil
  • Universidade Federal Do Ceara
    Fortaleza, 60020-181, Brazil
  • Instituto Bairral de Psiquiatria
    Itapira, 13970-905, Brazil
  • Faculdade de Medicina da Universidade Federal de Pelotas
    Pelotas, 96030-002, Brazil
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Universidade Federal do Rio de Janeiro - Instituto de Psiquiatria
    Rio de Janeiro, 22290-140, Brazil
  • Hospital Universitario Professor Edgar Santos
    Salvador, 40110-060, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    Sao Paulo, 05403-903, Brazil
  • HOMO - ESE Hospital Mental de Antioquia
    Bello, 051053, Colombia
  • Instituto Colombiano del Sistema Nervioso
    Bogota, 110121, Colombia
  • Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
    Bogota, 111166, Colombia
  • Conciencia S.A.S
    Medellín - Antioquia, 050021, Colombia
  • Grupo de Estudios Médicos y familiares Carraci SC
    Ciudad de Mexico, 03740, Mexico
  • Estimulación Magnética Transcraneal de México S.C.
    Ciudad de Mexico, 11006, Mexico
  • Hospital Psiquiátrico Granja la Salud Tlazolteotl
    Ixtapaluca, 56530, Mexico
  • Hospital Aranda de la Parra S A de C V
    Leon, 37000, Mexico
  • Hospital Psiquiatrico Fray Bernardino Alvarez
    Mexico City, 14000, Mexico
  • Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz
    Mexico City, 14370, Mexico
  • Clínica de Neuropsiquiatría Tlatelolco ISSSTE
    Mexico city, 6900, Mexico
  • Instituto Nacional de Neurología y Neurocirugía
    Mexico, 14269, Mexico
  • Privarte Practice of Dr. Javier Zambrano
    Mexico, 15900, Mexico
  • Instituto Jalisciense de Salud Mental
    Mexico, 45170, Mexico
  • Centro para las Adicciones y Salud Mental S.A. de C.V.
    Monterrey, 64060, Mexico
  • cit NEUROPSIQUE
    Monterrey, 64610, Mexico
  • Hospital Central Dr Ignacio Morones Prieto
    San Luis Potosi, 78240, Mexico
  • Clínica de Consulta Externa Alfredo del Mazo Vélez ISSEMyM
    Toluca, 50080, Mexico
08

References and documents

Publications

  • Soares B, Kanevsky G, Teng CT, Perez-Esparza R, Bonetto GG, Lacerda ALT, Uribe ES, Cordoba R, Lupo C, Samora AM, Cabrera P. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study. Psychiatr Q. 2021 Dec;92(4):1797-1815. doi: 10.1007/s11126-021-09930-x. Epub 2021 Aug 31. PubMed 34463905 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2019, 25 months.

Of 33 observational studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Jul 2, 2017
StartActual
Sep 27, 2017
Primary completionActual
Nov 25, 2019
CompletionActual
Nov 25, 2019
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03207282
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Sep 27, 2017
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Last update
Apr 27, 2025

Study contacts

Jannsen Cilag S.A. Clinical Trial
study director · Jannsen Cilag S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion